<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00360893</url>
  </required_header>
  <id_info>
    <org_study_id>N01-DK-6-2204</org_study_id>
    <secondary_id>U01DK094176</secondary_id>
    <nct_id>NCT00360893</nct_id>
  </id_info>
  <brief_title>Epidemiology of Diabetes Interventions and Complications (EDIC)</brief_title>
  <official_title>Epidemiology of Diabetes Interventions and Complications (EDIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The Diabetes Control and Complications Trial (DCCT) demonstrated the powerful
      impact of glycemic control on the early manifestations of microvascular complications.
      Contemporary prospective data on the evolution of macrovascular and late microvascular
      complications of type 1 diabetes are limited. The Epidemiology of Diabetes Interventions and
      Complications (EDIC) study is a multi-center, longitudinal, observational study designed to
      utilize the well-characterized DCCT cohort of ~1,400 participants to determine the long-term
      effects of prior separation of glycemic levels on micro- and macrovascular outcomes. The
      current phase of EDIC also focuses on the interaction between and the effects of aging and
      long-duration diabetes on cognitive and physical function as well as the long-term effects of
      diabetes-related complications on quality-of-life and health care costs. EDIC is in its 27th
      year of follow-up.

      Methods: Data collection focuses on micro- and macrovascular complications. Annual or
      biennial measurements (using DCCT methods, standardized protocols and central laboratories)
      of vascular events, albumin excretion, GFR, ECG, ankle-brachial BP index, serum lipids and
      HbA1c allows the following analyses: 1) continuation of intention-to-treat analyses to
      determine long-term effects of prior separation of glycemic levels; 2) risk factors for
      macrovascular outcomes; 3) correlation of progression of micro- and macrovascular outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 1994</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">1441</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients enrolled in the DCCT
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A participant in the Diabetes Control and Complications Trial (DCCT)(N01-DK-6-2204-A).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>David M Nathan, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rose A Gugitosi-Klug, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Western Reserve University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John M. Lachin, Sc.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University, Biostatistics Center, Data Coordinating Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University, Clinical Coordinating Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto, Mount Sinai Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5t 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>DCCT/EDIC Research Group, Nathan DM, Bebu I, Hainsworth D, Klein R, Tamborlane W, Lorenzi G, Gubitosi-Klug R, Lachin JM. Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes. N Engl J Med. 2017 Apr 20;376(16):1507-1516. doi: 10.1056/NEJMoa1612836.</citation>
    <PMID>28423305</PMID>
  </results_reference>
  <results_reference>
    <citation>Writing Group for the DCCT/EDIC Research Group, Orchard TJ, Nathan DM, Zinman B, Cleary P, Brillon D, Backlund JY, Lachin JM. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015 Jan 6;313(1):45-53. doi: 10.1001/jama.2014.16107.</citation>
    <PMID>25562265</PMID>
  </results_reference>
  <results_reference>
    <citation>Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Musen G, Ryan CM, Silvers N, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Harth J. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med. 2007 May 3;356(18):1842-52. Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914.</citation>
    <PMID>17476010</PMID>
  </results_reference>
  <results_reference>
    <citation>Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005 Dec 22;353(25):2643-53.</citation>
    <PMID>16371630</PMID>
  </results_reference>
  <results_reference>
    <citation>Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group, Lachin JM, Genuth S, Cleary P, Davis MD, Nathan DM. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000 Feb 10;342(6):381-9. Erratum in: N Engl J Med 2000 May 4;342(18):1376.</citation>
    <PMID>10666428</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 3, 2006</study_first_submitted>
  <study_first_submitted_qc>August 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2006</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NIDDK Repository</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

